# Isarna Therapeutics

Source: https://onco.cc/companies/isarna-therapeutics/  
OnCo record `isarna-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Isarna, formerly Antisense Pharma, is a Munich company whose TGF-beta2 antisense drug trabedersen was tested directly into brain tumours in phase 3 for high-grade glioma before the programme moved to eye disease.

## Summary

Isarna Therapeutics, founded in Regensburg in 1998 as Antisense Pharma and now based in Munich, develops antisense oligonucleotides against transforming growth factor beta 2. Trabedersen (AP 12009), infused into the tumour, reached the phase 3 SAPPHIRE trial in anaplastic astrocytoma, which was stopped early, and the company has since focused on ophthalmology. Its trials remain on ClinicalTrials.gov under the company as lead sponsor.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Isarna Therapeutics GmbH; Antisense Pharma
- Tags: ctgov-sponsor
- HQ: Munich
- Type: biotech
- Website: http://www.isarna-therapeutics.com

## Sources

- Official website: http://www.isarna-therapeutics.com
- ClinicalTrials.gov: trials led by Isarna Therapeutics GmbH: https://clinicaltrials.gov/search?lead=Isarna%20Therapeutics%20GmbH
- Wikidata: https://www.wikidata.org/wiki/Q50038820

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- technologies: [Oligonucleotide therapeutics](https://onco.cc/technologies/antisense-sirna/)
- pathways: [TGF-β signalling](https://onco.cc/pathways/tgf-beta/)
- terms: [Clinical trial](https://onco.cc/terms/clinical-trial/), [Pivotal (registrational) trial](https://onco.cc/terms/pivotal-trial/)

---
JSON: https://onco.cc/api/v1/entities/isarna-therapeutics.json